Indeed, in some neuroendocrine and pituitary tumors, a truncated or spliced SSTR5 variant blocks SSTR2 signaling, which explains the lack of effect of SST analogues in these tumors, even in the presence of normal SSTR2 expression [17]. Here, SSTR2 is linked to pituitary tumor.